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Cancer-speciﬁc PERK signaling drives invasion and
metastasis through CREB3L1
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PERK signaling is required for cancer invasion and there is interest in targeting this pathway
for therapy. Unfortunately, chemical inhibitors of PERK’s kinase activity cause on-target side
effects that have precluded their further development. One strategy for resolving this difﬁ-
culty would be to target downstream components of the pathway that speciﬁcally mediate
PERK’s pro-invasive and metastatic functions. Here we identify the transcription factor
CREB3L1 as an essential mediator of PERK’s pro-metastatic functions in breast cancer.
CREB3L1 acts downstream of PERK, speciﬁcally in the mesenchymal subtype of triple-
negative tumors, and its inhibition by genetic or pharmacological methods suppresses cancer
cell invasion and metastasis. In patients with this tumor subtype, CREB3L1 expression is
predictive of distant metastasis. These ﬁndings establish CREB3L1 as a key downstream
mediator of PERK-driven metastasis and a druggable target for breast cancer therapy.
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The PERK kinase plays a critical role in tumor invasion andmetastasis. PERK signaling—which is activated down-stream of the unfolded protein response (UPR)1, 2 and the
integrated stress response3—enables cancer cells to survive the
adverse conditions typically observed in tumor microenviron-
ments4–6. Upon its activation, PERK phosphorylates eIF2a, which
reduces global protein synthesis while selectively increasing the
translation of ATF47. In addition to enabling cell survival,
PERK–ATF4 signaling triggers multiple steps in the metastatic
cascade8, including angiogenesis9, migration10, survival11, and
colonization at secondary organ sites12. PERK is also required for
the metastatic dissemination of cancer cells that have undergone
an epithelial-to-mesenchymal transition (EMT)13.
Given its critical role in driving metastatic progression, PERK
has been a focus of drug discovery programs for cancer,
which have identiﬁed several small-molecule inhibitors of this
kinase that reduce metastatic dissemination13. While these
molecules reduce metastatic spread, they also cause rapid
onset of pancreatic atrophy, precluding their further considera-
tion for clinical development14. Since similar phenotypes are
observed in PERK-knockout mice, PERK is likely to be essential
for normal pancreatic function15, 16. This has raised concerns
about whether this key pathway is a viable target for therapy. One
way to circumvent this difﬁculty would be to target downstream
factors that speciﬁcally mediate PERK’s pro-metastatic functions,
but do not contribute to the pathway’s functions in non-
cancerous tissues. While this strategy is promising in principle, it
is not currently known if the PERK pathway’s pro-metastatic
functions can be genetically separated from its role in normal
homeostasis.
In this study, we show that this is indeed the case, and identify
a key transcription factor (CREB3L1) downstream in the path-
way, that speciﬁcally functions to promote metastasis in cancer
cells that have activated PERK. Since CREB3L1 must be proteo-
lytically cleaved in order to become active, this provides a unique
opportunity to target this factor with small-molecule inhibitors
for therapy17. While CREB3L1’s role in cancer is currently con-
troversial—with some studies suggesting that this factor promotes
metastasis, and others suggesting it suppresses metastasis18, 19—
we resolve this discrepancy by showing that CREB3L1 speciﬁcally
promotes metastasis in tumors that have activated both PERK
signaling and the EMT program. Collectively, our ﬁndings
establish CREB3L1 as a promising target downstream of the
PERK pathway for therapeutic blockade in cancer.
Results
Cancer-speciﬁc PERK signaling correlates with metastasis.
Consistent with prior reports13, we found that PERK is activated
by phosphorylation in human breast cancers (Supplementary
Fig. 1a). To identify factors downstream of PERK speciﬁcally
upregulated in human breast cancers, we compared PERK
pathway gene expression between a large cohort of breast cancers
(n= 1093) and normal breast tissues (n= 112) (TCGA, breast
cancer data set). Of the ~400 genes downstream of PERK20
(Supplementary Data 1), only 23 showed at least a twofold
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Fig. 1 Cancer-speciﬁc PERK signaling correlates with progression and metastasis. a A volcano plot comparing the expression of 388 PERK pathway genes
between breast cancer tissues and normal breast tissues. Plotted for each gene are the negative log10 of the p value and the log2 of the fold change of gene
expression of cancer samples relative to normal samples. A set of 23 genes that are twofold overexpressed in cancer and signiﬁcant after Bonferroni
correction were deﬁned as the cancer-speciﬁc PERK set (CSPS; red dots). b A heat map showing the expression of the CSPS genes across 112 normal breast
samples and 1093 breast tumors. c–e Average expression of CSPS genes was used to examine survival in breast, lung, and gastric tumor data sets. Patients
were binned into CSPS high (top tertile) and CSPS low (bottom tertile), and survival curves were plotted. A cohort of c breast cancers was analyzed for
metastasis-free survival (GSE17907, GSE9195, GSE20685, GSE16446, and GSE19615, n= 182 for each arm). A cohort of d lung cancers and e gastric
cancers were analyzed for progression-free survival (lung cancer: GSE8894, GSE50081, GSE29013, and GSE31210, n= 195 for each arm; gastric cancer:
GSE22377, GSE15459, and GSE62254, n= 167 for each arm). The indicated p-values were calculated using the log-rank test
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increase in expression in cancers relative to normal tissues
(Fig. 1a, b; CSPS, cancer-speciﬁc PERK set). Expression of these
genes depended on PERK activity, since inhibition of PERK with
a small-molecule inhibitor (GSK265615714) led to a signiﬁcant
decrease in the expression of 18 out of 23 CSPS genes (Supple-
mentary Fig. 1b). Breast cancers that highly expressed these
cancer-speciﬁc PERK genes were signiﬁcantly more likely to
develop distant metastases over 10 years (HR= 1.8, p< 0.005,
log-rank test; Fig. 1c). Expression of these genes was also predic-
tive of tumor progression in lung and gastric cancers (Fig. 1d, e).
CREB3L1 upregulates CSPS genes and is required for invasion.
CREB3L1 was the only transcription factor among the cancer-
speciﬁc PERK genes we identiﬁed (Fig. 1a, b). Analysis of
ChIP-seq data indicated that CREB3L1 was enriched near CSPS
gene loci (14/23 genes, p< 0.01, binomial test; Fig. 2a and
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Fig. 2 CREB3L1 upregulates cancer-speciﬁc PERK genes and is required for invasion. a Distribution of CREB3L1 ChIP-seq fold-enrichment over input control,
along with called-peaks, at the locus of CSPS genes. Shown were the CREB3L1 peaks for three CSPS genes: MMP11, COL1A2, and SLC20A1. b A pie chart
showing the fraction of CREB3L1 ChIP-Seq peaks from the CSPS genes that were co-localized with acetylated H3K27. c qPCR showing the relative
expression of the CSPS genes shown in a in SUM159 and MDA.MB.231 cells transduced with shRNAs targeting luciferase or CREB3L1, n= 4. d
Quantiﬁcation of the cell invasion of SUM159 cells transduced with shRNAs targeting luciferase or CREB3L1 in a basement membrane-coated transwell
assay, n= 3. e Left panel: quantiﬁcation of colony types formed by SUM159 cells transduced with shRNAs targeting luciferase or CREB3L1 in a 7-day 3D
Matrigel invasion assay, n= 50; right panel: representative images of benign, intermediate, and invasive colonies (scale bar: 80 µm). f Schematic of full-
length CREB3L1 and CREB3L1Δ375-519. g Quantiﬁcation of cell invasion of HMLE cells transduced with control plasmid or a constitutive active form of
CREB3L1 (CREB3L1Δ375–519) in a basement membrane-coated transwell assay, n= 3. h Western blotting of phospho-FAK (pY397 and pY576), total FAK,
and Actin in SUM159 cells transduced with shRNAs targeting luciferase or CREB3L1. i Quantiﬁcation of cell migration of SUM159 cells transduced with
shRNAs targeting luciferase or CREB3L1 treated with the indicated conditions, n= 8. Data are represented as mean± SEM. * indicates p< 0.05; ** indicates
p< 0.01 (Student’s t-test)
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Supplementary Fig. 2a); CREB3L1 was localized to active reg-
ulatory regions marked by H3K27-acetylated histones (86% of
bound sites; Fig. 2b)21. To functionally assess CREB3L1’s role in
regulating these genes, we used shRNAs to stably inhibit
CREB3L1 expression in two invasive breast cancer cell lines,
SUM159 and MDA.MB.231 (Supplementary Fig. 2b). Inhibiting
CREB3L1 reduced the expression of 10 of these 14 CSPS genes
(Fig. 2c and Supplementary Fig. 2c). Taken together, these data
indicated that CREB3L1 directly promotes the transcription of
CSPS genes.
We next used three approaches to assess if CREB3L1 was
required for cancer cell invasion. First, we compared CREB3L1
expression between non-invasive and invasive breast cancer
lines22, 23, which revealed that this factor’s expression was
increased over 50-fold in the invasive lines (Supplementary
Fig. 3a). Second, we inhibited CREB3L1 expression to test if it was
required for the invasiveness of invasive cancer lines. In both the
SUM159 and MDA.MB.231 lines, CREB3L1 inhibition caused a
sixfold reduction in cellular invasion through basement
membrane-coated transwell chambers (Fig. 2d and Supplemen-
tary Fig. 3b). In contrast, knockdown of CREB3L1 does not affect
cell growth of SUM159 and MDA.MB.231 cells (Supplementary
Fig. 3c, d). Lastly, we tested the requirement of CREB3L1 for
invasion in 3D. When seeded as single cells into 3D cultures in
basement membrane, SUM159 and MDA.MB.231 breast cancer
lines form clonal structures that can be classiﬁed as benign (non-
invasive), intermediate (partially invasive), or invasive. Knock-
down of CREB3L1 prevented the formation of invasive spheroids,
while increasing the formation of non-invasive spheroids (Fig. 2e
and Supplementary Fig. 3e).
CREB3L1 is localized to ER membranes and can migrate to the
nucleus to activate transcription. Its nuclear migration is triggered
via cleavage by the site 1 (S1P) and site 2 proteases (S2P), which
produces an activated, truncated form of CREB3L124; the
truncated CREB3L1 is then free to migrate into the nucleus and
activate transcription (Fig. 2f). Both the full length and truncated
form of CREB3L1 were upregulated in invasive cancer cells when
compared to non-invasive cells (Supplementary Fig. 3f). We
found that the aforementioned decrease in invasive spheroids
following knockdown of CREB3L1 is rescued by overexpression
of a constitutively active form of CREB3L1 (CREB3L1Δ375–519;
Supplementary Fig. 3g, h). Next, we examined if CREB3L1 was
sufﬁcient to promote invasion in non-invasive cells. Over-
expression of CREB3L1Δ375–519 resulted in a fourfold increase
in cellular invasion in a non-invasive HMLE cell line (Fig. 2g),
indicating that CREB3L1’s expression was sufﬁcient to promote
invasion.
CREB3L1-induced ECM deposition activates FAK. To further
explore the mechanism through which CREB3L1 promotes
invasion, we performed gene ontology analysis of CREB3L1-
regulated CSPS genes. The analysis suggested that CREB3L1
might regulate ECM production and remodeling (Supplementary
Fig. 4a; p< 10−5, hypergeometric test), key processes associated
with cancer cell invasion. Consistent with this, CREB3L1 inhi-
bition strongly reduced activation of FAK—a kinase regulated by
cell–ECM interactions and known to be important for cellular
migration (Fig. 2h)25, 26. To assess if CREB3L1 was important for
migration, we seeded CREB3L1-inhibited or control cells into
transwell chambers. We found that CREB3L1 inhibition caused a
ﬁvefold reduction in migratory potential (Supplementary Fig. 4b).
Since CREB3L1 regulates the expression of ECM genes, e.g.,
COL1A2 and FN1 (Fig. 2c and Supplementary Fig. 2c), we
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Fig. 3 CREB3L1 is required for metastasis and is upregulated in the metastases of breast cancer patients. a A quantiﬁcation of circulating tumor cells
(CTCs) per ml of blood from NOD/SCID mice 7 weeks after being transplanted with MDA.MB.231-Luc-LM2 cells transduced with shRNAs targeting LacZ
or CREB3L1, n= 5. b Lung metastases of the animals in a were quantiﬁed (top) by radiance of the whole lung in each animal, n= 5. Total radiance was also
imaged (bottom). c Lung metastases of the animals in a was gauged by immunohistochemistry staining for GFP-positive cancer cells in lung sections. GFP
area per ﬁeld was quantiﬁed (top) and imaged (bottom), n= 10,10,9 for Ctrl, sh1, and sh2, respectively (scale bar: 40 µm). d Expression of CREB3L1 in 529
primary breast cancer tissues and 45 breast cancer metastases (GSE20565, GSE20685, GSE7904, and GSE3744) shown as a box-and-whiskers plot. e
Immunohistochemical staining for CREB3L1 in a tissue microarray containing primary breast cancer tissues (left, n= 50) and breast cancer metastases in
lymph nodes (middle, n= 50). Nuclear CREB3L1 levels were quantiﬁed (right). Scale bar: 40 µm. Data are represented as mean± SEM or the mean alone. *
indicates p< 0.05; ** indicates p< 0.01 (Student’s t-test)
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hypothesized that its inhibition could be reducing FAK activity by
decreasing ECM production. Consistent with this, addition of
type I collagen (encoded by COL1A1 and COL1A2) rescued FAK
activity in the CREB3L1-inhibited cells (Supplementary Fig. 4c).
If CREB3L1’s pro-invasive effects were arising through ECM
production, it should be possible to rescue the migration of
CREB3L1-inhibited cells by supplementing them with exogenous
pro-invasive ECM. In fact, cells inhibited for CREB3L1 expres-
sion were able to better heal wounds when treated with exogen-
ous type I collagen or ﬁbronectin (Fig. 2i). Collectively, these
results suggested that CREB3L1 may promote migration and
invasion by inducing ECM production.
CREB3L1 is required for breast cancer metastasis. We next
assessed CREB3L1’s role in vivo using the MDA.MB.231-LM2
orthotopic transplantation model of human breast cancer, which
forms tumors that invade the vasculature and metastasize to the
lungs. While CREB3L1 inhibition does not affect primary tumor
formation or growth, as indicated by similar tumor weights and
Ki67-positive proliferative indices (Supplementary Fig. 5), there
was a >80-fold reduction in the number of circulating tumor cells
(CTCs) (Fig. 3a). Moreover, CREB3L1 inhibition resulted in a
>400-fold reduction in lung metastases, as measured both by
luminescence emitted by metastatic cells in whole lungs, as well as
by immunohistochemistry staining for GFP-positive cancer cells
in lung sections (Fig. 3b, c). These ﬁndings indicated that
CREB3L1 was required for cancer cells to enter into the circu-
lation and form metastases.
To assess the clinical relevance of these ﬁndings, we examined
CREB3L1 expression in primary breast cancers and metastatic
breast cancers from patients. In comparison with primary breast
cancer tissues, CREB3L1 gene expression was signiﬁcantly
upregulated in the metastatic growths of breast cancers that
had disseminated to distant organ sites (p< 0.01, Student's t-test;
Fig. 3d, GSE20565, GSE20685, GSE7904, and GSE3744). Con-
sistent with these ﬁndings, nuclear and total CREB3L1 protein
were expressed at signiﬁcantly higher levels in the lymph node
metastases of breast cancers, relative to primary breast tumors
present on the same tissue microarray (Fig. 3e).
These ﬁndings indicated that CREB3L1 is required for
metastatic dissemination in animal models of breast cancer, and
is upregulated in the breast cancers of patients as they progress
toward metastatic disease.
Chemical inhibition of CREB3L1 blocks metastasis. Although
most transcription factors are currently not “druggable”,
CREB3L1’s unique mechanism of activation provides an oppor-
tunity to target its activity using protease inhibitors. A chemical
inhibitor of proteases, AEBSF, has been used previously to inhibit
the protease (S1P) that cleaves CREB3L1 to its active form24, 27.
In SUM159 cells, AEBSF treatment blocked cleavage of
FLAG-CREB3L1full-length protein to its active form, but had no
effect on the levels of FLAG-CREB3L1Δ375–519 protein (Fig. 4a).
Consistent with this, AEBSF treatment decreased the expression
of CREB3L1 target genes COL1A128 and COL1A2 (Fig. 4b).
However, AEBSF treatment did not decrease the expression of
these genes in cells expressing the constitutively active
FLAG-CREB3L1Δ375–519 (Fig. 4b). While this ﬁnding was
expected, because this truncated protein does not need to be
cleaved to become active, it nonetheless indicated that AEBSF’s
effects on COL1A1 and COL1A2 were mediated by CREB3L1.
Inhibition of CREB3L1 activation by another S1P inhibitor,
PF429242, also decreased the expression of COL1A1 and
COL1A2, which could be rescued by expression of FLAG-
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Fig. 4 Chemical inhibition of CREB3L1 blocks metastasis. a A western blot of CREB3L1 expression in full-length CREB3L1 or CREB3L1Δ375–519 transduced
SUM159 cells that were treated with solvent control or a S1P inhibitor, AEBSF. b SUM159 cells transduced with control or CREB3L1Δ375–519 were treated
with solvent control or AEBSF. qPCR analyses were performed to quantify the expression of ECM genes: COL1A1 and COL1A2. The gene expression was
normalized to the solvent-treated control transduction samples, n= 3. c Western blot of phosphorylated FAK (pY397 and pY576), total FAK, and Tubulin
in cells of b. d Quantiﬁcation of cell invasion of cells from b in a basement membrane-coated transwell assay, n= 3. e Two weeks after orthotopical
transplantation with control or CREB3L1Δ375–519 transduced MDA.MB.231-Luc-LM2 cells, NOD/SCID mice were treated with solvent control or AEBSF for
another 4 weeks. Lung metastases of the animals were gauged by radiance from the whole lung in each animal, n= 9. Data are represented as mean±
SEM or geometric mean alone. * indicates p< 0.05; ** indicates p< 0.01 (Student’s t-test)
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CREB3L1Δ375–519 (Supplementary Fig. 6a). In addition, AEBSF
treatment strongly reduced FAK phosphorylation, which could be
restored by expression of FLAG-CREB3L1Δ375–519 (Fig. 4c).
Furthermore, inhibition of CREB3L1 activation by AEBSF or
PF429242 signiﬁcantly negated the invasiveness of the SUM159
cells, an effect that can be rescued by overexpression of the
truncated FLAG-CREB3L1Δ375–519 (Fig. 4d and Supplementary
Fig. 6b–d). In contrast, overexpression of the constitutively active
form of two other targets of AEBSF, ATF6 and SREBP-1, was not
able to rescue the decrease of cell invasion caused by AEBSF
(Supplementary Fig. 6e, f). These results showed that AEBSF
inhibits invasion through targeting CREB3L1.
We next assessed if treatment with AEBSF could inhibit
metastasis in vivo in the orthotopic MDA.MB.231-LM2 model of
human breast cancer. While AEBSF did not affect primary tumor
growth (Supplementary Fig. 7a, b), it caused a 15-fold reduction
in lung metastases, as measured by luminescence emitted from
whole lungs (Fig. 4e). However, AEBSF was not able to inhibit the
metastasis of LM2 tumors that overexpressed
FLAG-CREB3L1Δ375–519, indicating that its effects were mediated
through CREB3L1. These observations suggest that inhibiting S1P
activity to block CREB3L1 activation could be an effective
therapeutic strategy for preventing metastasis.
PERK signaling requires an EMT to upregulate CREB3L1.
Lastly, we investigated how this factor is regulated in invasive
cancer cells. Consistent with the ﬁnding that CREB3L1 is
downstream of PERK signaling (Supplementary Fig. 8), inhibition
of ATF4 expression decreased CREB3L1 transcription in MDA.
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cohorts, according to the expression of CREB3L1. Gene set enrichment analysis using the hallmark gene sets was performed to compare the CREB3L1-high
and CREB3L1-low tumors (left). The top hallmark gene set was an EMT set (right). d qPCR showing the relative expression of CREB3L1 in HMLE cells
overexpressing ATF4 with or without induction of an EMT, n= 3. Data are represented as mean± SEM. * indicates p< 0.05; ** indicates p< 0.01
(Student’s t-test). e Expression of CREB3L1 in breast cancers (TCGA) that have differential levels of PERK signaling and EMT signaling as indicated. Data
are represented as a box-and-whiskers plot, n= 122. * indicates p< 0.05; ** indicates p< 0.01 (Mann–Whitney U-test). f HMLE cells were transduced with
ATF4 and Fra-1 expressing constructs. Western blot for ATF4 or Fra-1 after immunoprecipitation of either ATF4 or Fra-1, which shows that these factors
co-immunoprecipitate each other. g qPCR showing the relative expression of CREB3L1 in HMLE cells overexpressing control, ATF4, Fra-1, or a combination
of ATF4 and Fra-1, n= 3. Data are represented as mean± SEM. * indicates p< 0.05; ** indicates p< 0.01 (Student’s t-test)
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MB.231 and SUM159 lines (Fig. 5a). Surprisingly, overexpression
of ATF4 in non-invasive lines (HMLE and T47D) is not sufﬁcient
to activate transcription of CREB3L1, suggesting that PERK sig-
naling requires additional pathways to induce CREB3L1 (Fig. 5b).
To explore these additional pathways, we segregated breast can-
cers that have active PERK signaling into two categories
according to the expression level of CREB3L1 (CREB3L1-high
and CREB3L1-low, respectively), and employed gene set enrich-
ment analysis (GSEA) to compare these two cohorts (Fig. 5c). We
found that the EMT hallmark set was the most enriched pathway
in tumors that had high CREB3L1 expression relative to those
with low CREB3L1 expression (Fig. 5c). This implicated EMT
signaling as a potential regulator of CREB3L1 expression in the
context of PERK activation. To functionally assess this, we
assayed CREB3L1 expression with or without EMT induction in
cells overexpressing ATF4. We found that HMLE cells induced
into EMT had a greater than ﬁvefold higher CREB3L1 expression
than those that were not (Fig. 5d). Consistently, expression of
CREB3L1 was highest in breast tumors that have both active
PERK signaling and EMT signaling (Fig. 5e). Furthermore,
expression of CREB3L1 is predictive of distant metastasis-free
survival in patients with triple-negative breast cancer of the
mesenchymal subtype, which is usually enriched for pathways
associated with EMT (Supplementary Fig. 9)29.
We next further dissected which component of EMT signaling
cooperates with PERK signaling to induce CREB3L1. Using the
proteomic interaction database, Biogrid, we found that ATF4
might interact with Fra-1, a potent EMT transcription factor30, 31.
By performing co-immunoprecipitation, we validated that ATF4
interacts with Fra-1 in HMLE cells (Fig. 5f). Double over-
expression of ATF4 and Fra-1 strongly induces the expression of
CREB3L1 in non-EMT HMLE cells, while single overexpression
of either gene is not sufﬁcient to induce CREB3L1 (Fig. 5g and
Supplementary Fig. 10). These results suggested that PERK
signaling requires EMT to upregulate CREB3L1 through an
ATF4–Fra-1 interaction.
Discussion
The present ﬁndings establish CREB3L1 as a key downstream
mediator of PERK’s pro-metastatic function in cancers.
CREB3L1’s unique mode of activation makes it amenable—unlike
the vast majority of transcription factors—to inhibition by small
molecules. Thus, our ﬁndings identify a viable new avenue for
therapeutically targeting the PERK pathway in cancer.
The phenotypes observed in prior studies with transgenic mice
provide strong support for the notion that targeting CREB3L1
would circumvent the toxicities associated with PERK inhibitors.
While CREB3L1-knockout mice only have bone defects28, PERK-
knockout mice exhibit not only these bone defects, but also
reduced birth rates and develop diabetes15, 16, 32, 33. Additionally,
mice lacking ATF4—which is upstream of CREB3L1 but down-
stream of PERK—also have bone defects, lower birth rates, and
develop anemia34–37. These additional deﬁciencies strongly sug-
gest that both PERK and ATF4 have CREB3L1-independent
functions. In fact, in addition to activating CREB3L1, PERK also
activates NRF2—a transcriptional regulator of the cellular anti-
oxidant response38—whereas ATF4 also activates the transcrip-
tion of CHOP and BiP39. These observations are in consonance
with the general principle that upstream components of signaling
pathways typically have more pleotropic effects when compared
to downstream components.
While our results provide a proof-of-concept for inhibiting
PERK-CREB3L1 signaling in vivo, the use of site 1 protease (S1P)
inhibitors may raise concerns regarding drug speciﬁcity. Three
additional ER-bound transcription factors, ATF6 and SREBP-1/2,
are also affected by agents that inhibit S1P/S2P-mediated
proteolysis40. However, our data indicate that these factors are
not required for cell invasion, precluding their role in mediating
the anti-invasive effects of AEBSF in our experiments. Moreover,
Nelﬁnavir, a S2P inhibitor used in treating HIV patients, has been
well tolerated in clinical trials41, indicating that inhibition of
ATF6 and SREBP-1 is not likely to be problematic in patients.
Defects in ECM remodeling are hallmarks of human diseases—
including cancer and ﬁbrosis42, 43—and are frequently associated
with increased UPR signaling2, 44. Our ﬁndings provide the ﬁrst
molecular explanation for how PERK might regulate ECM
remodeling, namely through activation of CREBL1. Consistent
with this model, S1P inhibition—which would inhibit CREB3L1
—has also been shown to signiﬁcantly decrease expression of
ECM genes, including COL1A1, COL1A2, and FN127. This model
also explains the bone defects observed in CREB3L1, ATF4, and
PERK-knockout mice. The primary function of osteoblasts is to
produce ECM, which spontaneously mineralizes to form bone45.
Our results would suggest that these bone defects arise because
osteoblasts in CREB3L1, ATF4, and PERK-knockout mice pro-
duce insufﬁcient ECM36, 37. In fact, a prior study has shown that
expression of COL1A1 and COL1A2 is signiﬁcantly reduced in
CREB3L1-knockout mice28—consistent with our ﬁnding that
CREB3L1 regulates these collagens in invasive cancer cells.
Our observations indicate that the signaling downstream of
PERK activation is highly dependent on the differentiation state
of cancer cells. Thus, while PERK induces CREB3L1 in cancer
cells that have undergone an EMT, it fails to do so in cells that
have not undergone an EMT. Consistent with this, although
PERK is required for invasion in cancer cells that have undergone
an EMT, its activation is insufﬁcient to drive invasion in a
non-EMT context13. This suggests that CREB3L1 speciﬁcally
promotes metastasis in tumors that have activated both PERK
signaling and the EMT program. This observation may provide
an explanation for the conﬂicting reports in the literature
regarding CREB3L1’s role in metastasis18, 19. More generally, our
ﬁndings suggest that the ability of stress signaling to promote
metastasis will depend on the differentiation state of tumors.
Our observations provide a new avenue for treating the
mesenchymal subtype of triple-negative breast cancers (TNBC).
As a class, TNBCs afford a relatively poor prognosis, and are
therefore the focus of molecular subtyping and drug development
efforts29, 46. We have found that CREB3L1 expression strongly
correlates with the metastatic potential of this subtype of TNBCs.
Since the mechanism through which CREB3L1 is activated can be
effectively targeted by small-molecule inhibitors, our ﬁndings
suggest a promising new therapeutic strategy for this clinically
important subtype of breast cancer.
Methods
Human cell lines and culture conditions. MCF7, T47D, BT474, BT549, ZR-75-30,
Hs578T, MDA-MB-157, and MDA.MB.231 were obtained from the American
Type Culture Collection (ATCC), and were cultured in DMEM + 10% FBS.
SUM159 cells were obtained from Asterand, and were cultured in F12 + 5% FBS,
insulin (10 µg/ml), and hydrocortisone (0.5 µg/ml). MDA.MB.231-luc-LM2 (LM2)
cells were a kind gift from Dr Joan Massagué and cultured in DMEM + 10% FBS.
HMLE cells expressing the coding sequence of Twist1 fused to the mutated
estrogen receptor (HMLE-TwER) were obtained from Dr Robert A. Weinberg’s
lab, and maintained in a 1:1 mixture of DMEM+ 10% FBS, insulin (10 µg/ml),
hydrocortisone (0.5 µg/ml), EGF (10 ng/ml), and MEGM. To induce an EMT, the
HMLE cells were treated with 25 nM of 4-hydroxy-tamoxifen (4-OHT) for a period
of 12 days.
Lentiviral production and infection. Lentiviral particles were produced by
co-transfection with 0.25 µg pCMV-VSV-G, 0.75 µg pCMV-dR8.2-dvpr, and 1 µg
pLKO-shRNAs into 5 × 105 293T cells using 6 µl Fugene 6. Cell culture media of
293T cells were harvested 24, 48, and 72 h post transfection. After harvesting,
lentiviral transduction was performed in the presence of protamine sulfate by spin
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infecting for 1 h, then incubating overnight. Following transduction, cells were
selected using puromycin or blasticidin.
Plasmids. pCW-ATF4 was generated by digesting pCW57.1 (Addgene plasmid
#41393) with NheI and AgeI. ATF4-3xFlag-V5 was ampliﬁed with NheI and AgeI
overhangs and digested to insert into cut pCW57.1. pCW-CREB3L1Δ375–519 was
generated by cloning CREB3L1 without the amino acids between position 375 and
the C-terminus with NheI and AgeI overhangs, digested, and inserted into
pCW57.1 cut with NheI and AgeI. shATF4 and shCREB3L1 plasmids were from
the Broad Institute TRC platform. pLX304-FOSL1-3xFlag-V5 was generated by
digesting pLX304 (Addgene plasmid #25890) with BamHI and NheI. FOSL1-
3xFlag-V5 was ampliﬁed with BamHI and NheI overhangs and digested to insert
into cut pLX304. Cleaved N-terminus of ATF6 (1-373) and cleaved N-terminus of
SREBP-1-c (1-490) were from Addgene (Ron Prywes lab, Addgene plasmid #27173,
and Timothy Osborne lab, Addgene plasmid #26802). The pCW57.1 plasmid was a
gift from David Root (Addgene plasmid #41393) and pLKO.1-blast plasmid was a
gift from Keith Mostov (Addgene plasmid #26655).
Western blot and co-immunoprecipitation. Western blotting was performed
according to a previous study with the following modiﬁcations13. Cultured cells
were washed twice with PBS and lysed in radioimmunoprecipitation assay buffer
for 15 min on ice. Cell lysates were clariﬁed by centrifugation at 12,000×g for 10
min, and protein concentration was determined by the BCA Reagent. Lysates were
separated on NuPAGE 4–12% Bis-Tris gel electrophoresis, proteins were then
transferred to nitrocellulose membrane and immunoblotted with indicated anti-
bodies. All immunoblots were visualized by enhanced chemiluminescence. Anti-
bodies used for immunoblotting were as follows: ATF4 (Cell Signaling, 11815,
1:1000), Flag (Sigma, M2 clone, 1:10,000), GAPDH (Cell Signaling, 3683, 1:2000),
p-FAK (Cell Signaling, 8556 and 3281, 1:1000), Total FAK (Cell Signaling, 13009,
1:2000), and Fra-1 (Cell Signaling, 5281, 1:1000). In collagen rescue experiments,
culture plates were coated with type I collagen (EMD, CC050) for 1 h at room
temperature. Subsequently, 105 cells were seeded onto the collagen and grown for
24 h before protein harvest. In co-immunoprecipitation experiments, 5 × 107 cells
were seeded 24 h prior to harvesting. Whole cell lysate was collected and incubated
with 10 µl anti-Flag antibodies and 50 µl Dynabeads Protein G, or 10 µl anti-Fra-1
antibodies and 50 µl Dynabeads Protein A, respectively, for 24 h at 4 °C. Immu-
noprecipitants were eluted and analyzed by western blot. Raw data of all western
blots were included in Supplementary Fig. 11.
In vitro transwell assay. To assay migratory and invasive potential, we used a 24-
well 8-µm pore transwell plate coated without or with Matrigel, respectively
(Corning Inc.). Brieﬂy, we seeded 5 × 104 cells in the upper chamber, and incubated
the cells for 8 h before removing cells on the upper surface of the chamber to count
the number of cells that migrated onto the lower surface of the chamber. We use
crystal violet staining (Sigma-Aldrich) to label cells, and imaged ﬁve random ﬁelds
per well with a microscope at ×10. Images were then quantiﬁed using ImageJ.
In vitro wound healing migration assay. Total of 5 × 105 cells were seeded in six-
well plate 12 h prior to wound cutting. A 200 µl pipette tip was used to make
scratches on the single cell layer. Images of cells were taken immediately or 8 h after
wound cutting. All images were analyzed using ImageJ.
3D invasion assay. Basement membrane remodeling was assessed by seeding cells
in growth factor reduced Matrigel (BD Biosciences). Matrigel was thawed at 4 °C.
Then 100 µl of Matrigel was added to each chamber and allowed to solidify at 37 °C
with 5% CO2 in a humidiﬁed incubator for 30 min. A total of 500 single cells in a
200 µl suspension was seeded onto the initial layer of Matrigel and allowed to settle
for 20 min. An aliquot of 200 µl of media supplemented with 10% Matrigel was
gently layered on top. An aliquot of 200 µl of media was replaced every 4 days.
Cultures were ﬁxed and imaged 7 days after growth. Spheres were binned into three
categories based on invasiveness: benign, intermediate, and invasive. Benign
spheres were deﬁned as structures with no visible cellular protrusions, intermediate
spheres were deﬁned as structures with protrusions extending from a central col-
ony, and invasive structures were deﬁned as fully scattered colonies.
Spontaneous metastasis assay. NOD/SCID mice were purchased from Jackson
Labs. All mouse procedures were approved by the Animal Care and Use Com-
mittees of the Massachusetts Institute of Technology. For the spontaneous
metastasis assay, 1 × 106 MDA.MD.231-LM2 cells were suspended in 50 µl 1:1 mix
of Matrigel and DMEM, and injected into a mammary pad of each mouse. Animals
were randomized by weight before treatment. After 7 weeks, mice were weighed.
Tumors and lungs were harvested 7 weeks after injection. To measure metastases,
freshly collected lungs were soaked in D-Luciferin (150 μg/ml; PerkinElmer) for 15
min and imaged with the IVIS system (PerkinElmer) at non-saturating exposures.
Radiance was quantiﬁed with LivingImage v4.4 software. Tumors were weighed
after collection.
Drug treatment. In the chemical treatment experiment, 2 weeks after tumor cells
implantation, 200 µl pure PBS or PBS with 1 mg of AEBSF was administrated daily
through i.p. injection into the animals for a period of 4 weeks.
Immunohistochemistry and human tissue microarray. All immunohistochem-
istry was performed at the Koch Institute Histology Core using the Thermo Sci-
entiﬁc IHC Autostainer 360 (Thermo). Tumors obtained from the spontaneous
metastasis assay were ﬁxed in 10% neutral-buffered formalin, and then embedded
in parafﬁn. Parafﬁn-embedded tumors were sectioned at 5 µm for histological
analyses. Immunohistochemistry for Ki67 and GFP was performed. Stained sec-
tions were imaged and quantiﬁed. Brieﬂy, two ﬁelds were scored per animal,
resulting in a total of 10 ﬁelds per group. On each cross-section, ~5% of the total
area was scored for GFP positivity using ImageJ. Scores were normalized to the
mean of the control group to calculate relative lung metastasis. Tissue microarrays
were ordered from Biomax (BR10010d). Immunohistochemistry for CREB3L1 and
phosphorylated PERK (pPERK) was performed. CREB3L1 and pPERK staining
was independently quantiﬁed in a blinded manner. Antibodies used in IHC were:
GFP (Cell Signaling, 2956, 1:100), CREB3L1 (R&D systems, AF4080, 1:100), Ki67
(Cell Signaling, 9449, 1:250), and pPERK (PIERCE CHEMICAL MS, PA537773,
1:100).
Quantiﬁcation of circulating tumor cells. A total of 1 × 106 luciferase-labeled
MDA.MB.231-LM2 cells was inoculated into the fat pad of NOD/SCID mice. Seven
weeks post tumor implantation, 400 µl of peripheral blood samples was collected.
Blood samples were centrifuged at 1000×g to precipitate the cell fractions. An
aliquot of 1 ml of red blood cell lysis buffer (Stemcell Technology) was applied to
resuspend the pellet on ice for 5 min. The samples were then centrifuged again at
2000 rpm. An aliquot of 200 µl PBS containing luciferin was used to resuspend the
pellet, and luciferase activity of all samples were immediately measured using the
IVIS imaging system. To quantify the number of luciferase-positive cells, different
numbers of MDA.MB.231-LM2 cells, 1000, 333, 111, 37, and 12, were mixed with
400 μl of blood samples from tumor-free NOD/SCID mouse, respectively, and
followed by the same puriﬁcation and measurement processes mentioned above. A
linear relationship between luciferase activity and cell number was then generated
by linear regression, and the number of luciferase-positive circulating tumor cells
from tumor-bearing mice were then calculated.
GSEA and gene ontology analysis. We deﬁned the PERK gene set as the top 400
genes downregulated in an ATF4 knockout MEFs relative to wild-type MEFs fol-
lowing thapsigargin treatment (GSE35681). Gene symbols were converted to
human genes that overlapped with those in the TCGA data set, which left 388
remaining symbols. Gene ontology enrichment analysis for cellular components
was performed using the molecular signature database. Gene set enrichment
analysis was performed using the GSEA software developed by the Broad Institute.
PERKhigh patients were deﬁned as those whose scores for the PERK gene set ranked
in the top half. Subsequently, these PERKhigh patients were ranked based on
CREB3L1 expression. For each gene, expression from the top half (CREB3L1high)
of PERKhigh tumors were compared to those from the bottom half (CREB3L1low)
of PERKhigh tumors. Gene set enrichment analysis was performed using hallmark
gene sets provided by the molecular signature database on the ranked list of genes
produced by comparing CREB3L1high to CREB3L1low.
Chromatin immunoprecipitation. Chromatin immunoprecipitation was pre-
viously performed by the ENCODE Project using a CREB3L1 antibody
(Sigma-Aldrich, HPA024069) as described21. Library was downloaded from
ascension ENCLB300HOB. Reads were aligned to the human genome build
GRCh38 with up to one mismatch. Chip-seq peaks were identiﬁed using MACS2
with a q value threshold of 0.01. q value was calculated using the Benjamini-
Hochberg procedure. Each peak was annotated with the closest associated gene
using HOMER. CSPS bound genes were considered overlapping with H3K27ac if
they directly overlapped an H3K27ac peak. Distribution, as a fold change of
CREB3L1 signal relative to input signal, and peaks were displayed using UCSC
genome browser for hg38.
Primary tumor and metastasis gene expression analyses. Normalized RNA-seq
data were obtained from https://gdac.broadinstitute.org/. Data were log trans-
formed after adding a pseudocount. Gene expression for PERK signature genes was
binned into normal samples or tumor samples and was plotted as a heat map using
GENE-E. For each gene, a p value and the difference in log transformed expression
between cancer and normal was calculated.
For CREB3L1 expression across PERK and EMT bins, TCGA tumors were ﬁrst
binned into PERK-high or PERK-low bins based on if they were in the top 33
percentile or the bottom 33 percentile, respectively. For each PERK bin, EMT
signaling was categorized as high or low if it was in the top 33 percentile of the bin
or the bottom 33 percentile of the bin. For each tumor in each respective bin,
CREB3L1 expression was plotted.
For primary tumor vs. metastasis comparisons, GSE20565, GSE20685,
GSE7904, and GSE37444 were downloaded and quantile normalized. CREB3L1
expression across metastatic sites was compared to expression in primary tumors.
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Survival analysis. Clinical survival analyses were performed through an online
tool, KMplotter (kmplot.com)47. The information of data sets used was included in
Fig. 1. To calculate a score for the signatures, average gene expression for each
signature was determined. Patients were binned into those in the top tertile and
those in the bottom tertile for the signature score. Data were plotted as a
Kaplan–Meier curve.
Statistics. All statistical analyses were performed using Graphpad Prism software.
All data unless otherwise speciﬁed are presented as mean ± s.e.m. A two-tailed
Student’s t-test was performed for comparisons between two groups of data.
Signiﬁcance of gene ontological enrichment was calculated using the hypergeo-
metric test. Statistical signiﬁcance of Kaplan–Meier survival analysis was calculated
using the log-rank test. Signiﬁcance of CREB3L1 binding to the CSPS genes was
calculated using the binomial test. For each gene in tumor vs. normal comparisons,
p values were calculated using a Student’s t-test, where only those that surpassed
the Bonferroni-corrected threshold were considered signiﬁcant.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding authors on reasonable request.
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